Abstract
The medicinal chemistry and pharmacology of the four subtypes of adenosine receptors (ARs) and the eight subtypes of P2Y receptors (P2YRs, activated by a range of purine and pyrimidine mono- and dinucleotides) has recently advanced significantly leading to selective ligands. X-ray crystallographic structures of both agonist- and antagonist-bound forms of the A2AAR have provided unprecedented three-dimensional detail concerning molecular recognition in the binding site and the conformational changes in receptor activation. It is apparent that this ubiquitous cell signaling system has implications for understanding and treating many diseases. ATP and other nucleotides are readily released from intracellular sources under conditions of injury and organ stress, such as hypoxia, ischemia, or mechanical stress, and through channels and vesicular release. Adenosine may be generated extracellularly or by cellular release. Therefore, depending on pathophysiological factors, in a given tissue, there is often a tonic activation of one or more of the ARs or P2YRs that can be modulated by exogenous agents for a beneficial effect. Thus, this field has provided fertile ground for pharmaceutical development, leading to clinical trials of selective receptor ligands as imaging agents or for conditions including cardiac arrhythmias, ischemia/reperfusion injury, diabetes, pain, thrombosis, Parkinson’s disease, rheumatoid arthritis, psoriasis, dry eye disease, pulmonary diseases such as cystic fibrosis, glaucoma, cancer, chronic hepatitis C, and other diseases.
Similar content being viewed by others
Abbreviations
- AR:
-
Adenosine receptor
- EL:
-
Extracellular loop
- GPCR:
-
G protein-coupled receptor
- IL:
-
Intracellular loop
- TM:
-
Transmembrane helix
- NECA:
-
Adenosine-5′-N-ethyluronamide
- PD:
-
Parkinson’s disease
- PET:
-
Positron emission tomography
- SAR:
-
Structure–activity relationship
- SPECT:
-
Single photon emission tomography
- UDPG:
-
Uridine-5′-diphosphoglucose
References
Fredholm BB, IJzerman AP, Jacobson KA, Linden J, Müller C (2011) Nomenclature and classification of adenosine receptors—an update. Pharmacol Rev 63:1–34
Abbracchio MP, Burnstock G, Boeynaems JM, Barnard EA, Boyer JL, Kennedy C, Fumagalli M, King BF, Gachet C, Jacobson KA, Weisman GA (2006) International Union of Pharmacology LVIII. Update on the P2Y G protein-coupled nucleotide receptors: from molecular mechanisms and pathophysiology to therapy. Pharmacol Rev 58:281–341
Rittiner JE, Korboukh I, Hull-Ryde EA, Jin J, Janzen WP, Frye SV, Zylka MJ (2012) The nucleotide AMP is an adenosine A1 receptor agonist. J Biol Chem PMID:22215671, Jan 3. [Epub ahead of print]
Orriss I, Syberg S, Wang N, Robaye B, Gartland A, Jorgensen N, Arnett T, Boeynaems JM (2011) Bone phenotypes of P2 receptor knockout mice. Front Biosci (Schol Ed) 3:1038–1046
Klaasse EC, IJzerman AP, de Grip WJ, Beukers MW (2008) Internalization and desensitization of adenosine receptors. Purinergic Signal 4:21–37
Hechler B, Gachet C (2011) P2 receptors and platelet function. Purinergic Signal 4:293–303
Luo W, Wang Y, Reiser G (2011) Proteinase-activated receptors, nucleotide P2Y receptors, and μ-opioid receptor-1B are under the control of the type I transmembrane proteins p23 and p24A in post-Golgi trafficking. J Neurochem 117:71–81
Lazarowski ER, Sesma JI, Seminario-Vidal L, Kreda SM (2011) Molecular mechanisms of purine and pyrimidine nucleotide release. Adv Pharmacol 61:221–261
Kukulski F, Levesque SA, Sevigny J (2011) Impact of ectoenzymes on P2 and P1 receptor signaling. Adv Pharmacol 61:263–299
Fredriksson R, Lagerstrom MC, Lundin LG, Schioth HB (2003) The G-protein coupled receptors in the human genome form five main families. Phylogenetic analysis, paralogon groups, and fingerprints. Mol Pharmacol 63:1256–1272
Bjarnadottir TK, Gloriam DE, Hellstrand SH, Kristiansson H, Fredriksson R, Schiöth HB (2006) Comprehensive repertoire and phylogenetic analysis of the G protein-coupled receptors in human and mouse. Genomics 88:263–273
Jaakola VP, Griffith MT, Hanson MA, Cherezov V, Chien EY, Lane JR, IJzerman AP, Stevens RC (2008) The 2.6 angstrom crystal structure of a human A2A adenosine receptor bound to an antagonist. Science 322:1211–1217
Jaakola VP, Lane JR, Lin JY, Katritch V, IJzerman AP, Stevens RC (2010) Ligand binding and subtype selectivity of the human A2A adenosine receptor. Identification and characterization of essential amino acid residues. J Biol Chem 285:13032–13044
Ivanov AA, Barak D, Jacobson KA (2009) Evaluation of homology modeling of G protein-coupled receptors in light of the A2A adenosine receptor crystallographic structure. J Med Chem 52:3284–3292
Tosh DK, Phan K, Deflorian F, Wei Q, Gao ZG, Jacobson KA (2011) Truncated (N)-methanocarba nucleosides as A1 adenosine receptor agonists and partial agonists: overcoming lack of a recognition element. ACS Med Chem Lett 2:626–631
Dal Ben D, Lambertucci C, Marucci G, Volpini R, Cristalli G (2010) Adenosine receptor modeling: what does the A2A crystal structure tell us? Curr Top in Med Chem 10:993–1018
Doré AS, Robertson N, Errey JC, Ng I, Hollenstein K, Tehan B, Hurrell E, Bennett K, Congreve M, Magnani F, Tate CG, Weir M, Marshall FH (2011) Structure of the adenosine A2A receptor in complex with ZM241385 and the xanthines XAC and caffeine. Struct 19:1283–1293
Xu F, Wu H, Katritch V, Han GW, Jacobson KA, Gao ZG, Cherezov V, Stevens RC (2011) Structure of an agonist-bound human A2A adenosine receptor. Science 332:322–327
Lebon G, Warne T, Edwards PC, Bennett K, Langmead CJ, Leslie AG, Tate CG (2011) Agonist-bound adenosine A2A receptor structures reveal common features of GPCR activation. Nature 474:521–525
Ballesteros JA, Weinstein H (1995) Integrated methods for the construction of three dimensional models and computational probing of structure-function relations in G protein-coupled receptors. In: Conn PM, Sealfon SC (eds) Methods in Neurosciences, Vol. 25. Academic, USA, pp 366–428
Costanzi S, Mamedova L, Gao ZG, Jacobson KA (2004) Architecture of P2Y nucleotide receptors: Structural comparison based on sequence analysis, mutagenesis, and homology modeling. J Med Chem 47:5393–5404
Torres B, Zambon AC, Insel PA (2002) P2Y11 receptors activate adenylyl cyclase and contribute to nucleotide-promoted cAMP formation in MDCK-D1 cells. J Biol Chem 277:7761–7765
Hollopeter G, Jantzen HM, Vincent D, Li G, England L, Ramakrishnan V, Yang RB, Nurden P, Nurden A, Julius D, Conley PB (2001) Identification of the platelet ADP receptor targeted by antithrombotic drugs. Nature 409:202–207
Communi D, Gonzalez NS, Detheux M, Brezillon S, Lannoy V, Parmentier M, Boeynaems JM (2001) Identification of a novel human ADP receptor coupled to Gi. J Biol Chem 276:41479–41485
Moro S, Guo D, Camaioni E, Boyer JL, Harden TK, Jacobson KA (1998) Human P2Y1 receptor: molecular modeling and site-directed mutagenesis as tools to identify agonist and antagonist recognition sites. J Med Chem 41:1456–1466
van Rhee AM, Fischer B, van Galen PJ, Jacobson KA (1995) Modelling the P2Y purinoceptor using rhodopsin as template. Drug Design Discov 13:133–154
Jiang Q, Guo D, Lee BX, Van Rhee AM, Kim YC, Nicholas RA, Schachter J, Harden TK, Jacobson KA (1997) A mutational analysis of residues essential for ligand recognition at the human P2Y1 receptor. Mol Pharmacol 52:499–507
Erb L, Garrad R, Wang Y, Quinn T, Turner JT, Weisman GA (1995) Site-directed mutagenesis of P2U purinoceptors. Positively charged amino acids in transmembrane helices 6 and 7 affect agonist potency and specificity. J Biol Chem 270:4185–4188
Ecke D, Fischer B, Reiser G (2008) Diastereoselectivity of the P2Y11 nucleotide receptor: mutational analysis. Br J Pharmacol 155:1250–1255
Guo D, von Kügelgen I, Moro S, Kim YC, Jacobson KA (2002) Evidence for the recognition of non-nucleotide antagonists within the transmembrane domains of the human P2Y1 receptor. Drug Devel Res 57:173–181
Hillmann P, Ko GY, Spinrath A, Raulf A, von Kügelgen I, Wolff SC, Nicholas RA, Kostenis E, Höltje HD, Müller CE (2009) Key determinants of nucleotide-activated G protein-coupled P2Y2 receptor function revealed by chemical and pharmacological experiments, mutagenesis and homology modeling. J Med Chem 52:2762–2775
Hoffmann C, Moro S, Nicholas RA, Harden TK, Jacobson KA (1999) The role of amino acids in extracellular loops of the human P2Y1 receptor in surface expression and activation processes. J Biol Chem 274:14639–14647
Hoffmann K, Sixel U, Di Pasquale F, von Kügelgen I (2008) Involvement of basic amino acid residues in transmembrane regions 6 and 7 in agonist and antagonist recognition of the human platelet P2Y12-receptor. Biochem Pharmacol 76:1201–1213
Hoffmann K, Baqi Y, Morena MS, Glänzel M, Müller CE, von Kügelgen I (2009) Interaction of new, very potent non-nucleotide antagonists with Arg256 of the human platelet P2Y12 receptor. J Pharm Exp Therap 331:648–655
Ivanov AA, Ko H, Cosyn L, Maddileti S, Besada P, Fricks I, Costanzi S, Harden TK, Van Calenbergh S, Jacobson KA (2007) Molecular modeling of the human P2Y2 receptor and design of a selective agonist, 2′-amino-2′-deoxy-2-thiouridine 5′-triphosphate. J Med Chem 50:1166–1176
Qi AD, Zambon AC, Insel PA, Nicholas RA (2001) An arginine/glutamine difference at the juxtaposition of transmembrane domain 6 and the third extracellular loop contributes to the markedly different nucleotide selectivities of human and canine P2Y11 receptors. Mol Pharmacol 60:1375–1382
Teng R, Oliver S, Hayes MA, Butler K (2010) Absorption, distribution, metabolism, and excretion of ticagrelor in healthy subjects. Drug Metab Dispos 38:1514–1521
Nandanan E, Jang SY, Moro S, Kim HO, Siddiqui MA, Russ P, Marquez VE, Busson R, Herdewijn P, Harden TK, Boyer JL, Jacobson KA (2000) Synthesis, biological activity, and molecular modeling of ribose-modified deoxyadenosine bisphosphate analogues as P2Y1 receptor ligands. J Med Chem 43:829–842
Moro S, Jacobson KA (2002) Molecular modeling as a tool to investigate molecular recognition in P2Y receptors. Curr Pharmaceut Design 8:99–110
Major DT, Fischer B (2004) Molecular recognition in purinergic receptors. 1. A comprehensive computational study of the hP2Y1-receptor. J Med Chem 47:4391–4404
Major DT, Nahum V, Wang Y, Reiser G, Fischer B (2004) Molecular recognition in purinergic receptors. 2. Diastereoselectivity of the hP2Y1-receptor. J Med Chem 47:4405–4416
Jacobson KA, Costanzi S, Ivanov AA, Tchilibon S, Besada P, Gao ZG, Maddileti S, Harden TK (2006) Structure activity and molecular modeling analyses of ribose- and base-modified uridine 5′-triphosphate analogues at the human P2Y2 and P2Y4 receptors. Biochem Pharmacol 71:540–549
Costanzi S, Joshi BV, Maddileti S, Mamedova L, Gonzalez-Moa MJ, Marquez VE, Harden TK, Jacobson KA (2005) Human P2Y6 receptor: molecular modeling leads to the rational design of a novel agonist based on a unique conformational preference. J Med Chem 48:8108–8111
Besada P, Shin DH, Costanzi S, Ko H, Mathé C, Gagneron J, Gosselin G, Maddileti S, Harden TK, Jacobson KA (2006) Structure–activity relationships of uridine 5′-diphosphate analogues at the human P2Y6 receptor. J Med Chem 49:5532–5543
Zylberg J, Ecke D, Fischer B, Reiser G (2007) Structure and ligand-binding site characteristics of the human P2Y11 nucleotide receptor deduced from computational modelling and mutational analysis. Biochem J 405:277–286
Ivanov AA, Fricks I, Harden TK, Jacobson KA (2007) Molecular dynamics simulation of the P2Y14 receptor. Ligand docking and identification of a putative binding site of the distal hexose moiety. Bioorg Med Chem Lett 17:761–766
Mao Y, Zhang L, Jin J, Ashby B, Kunapuli SP (2010) Mutational analysis of residues important for ligand interaction with the human P2Y12 receptor. Eur J Pharmacol 644:10–16
Wu B, Chien EYT, Mol CD, Fenalti G, Liu W, Katritch V, Abagyan R, Brooun A, Wells P, Bi FC, Hamel DJ, Kuhn P, Handel TM, Cherezov V, Stevens RC (2010) Structures of the CXCR4 chemokine GPCR with small-molecule and cyclic peptide antagonists. Science 330:1066–1071
Deflorian F, Jacobson KA (2011) Comparison of three GPCR structural templates for modeling of the P2Y12 nucleotide receptor. J Comput Aided Mol Des 25:329–338
Maruoka H, Jayasekara MP, Barrett MO, Franklin DA, de Castro S, Kim N, Costanzi S, Harden TK, Jacobson KA (2011) Pyrimidine nucleotides with 4-alkyloxyimino and terminal tetraphosphate δ-ester modifications as selective agonists of the P2Y4 receptor. J Med Chem 54:4018–4033
Kalla RV, Zablocki J, Tabrizi MA, Baraldi PG (2009) Recent developments in A2B adenosine receptor ligands. In: HEP adenosine receptors in health and disease, Springer, Wilson C, Mustafa J (eds) Handb Exp Pharmacol 193:99–121
Baraldi PG, Tabrizi MA, Fruttarolo F, Romagnoli R, Preti D (2010) Recent improvements in the development of A2B adenosine receptor agonists. Purinergic Signal 5:3–19
Bauer A, Ishiwata K (2009) Adenosine receptor ligands and PET imaging of the CNS. Handb Exp Pharmacol 193:617–642
Jacobson KA, Gao ZG (2006) Adenosine receptors as therapeutic targets. Nature Rev Drug Disc 5:247–264
Müller C, Jacobson KA (2011) Recent developments in adenosine receptor ligands and their potential as novel drugs. BBA—Biomembranes 1808:1290–1308
Kiesman WF, Elzein E, Zablocki J (2009) A1 adenosine receptor antagonists, agonists, and allosteric enhancers. Handb Exp Pharmacol 193:25–58
Elzein E, Zablocki J (2008) A1 adenosine receptor agonists and their potential therapeutic applications. Expert Opin Investig Drugs 17:1901–1910
Wang Z, Do CW, Avila MY, Peterson-Yatorno K, Stone RA, Gao ZG, Joshi BV, Besada P, Jeong LS, Jacobson KA, Civan MM (2010) Nucleoside-derived antagonists to A3 adenosine receptors lower mouse intraocular pressure and act across species. Exp Eye Res 90:146–154
Franchetti P, Cappellacci L, Vita P, Petrelli R, Lavecchia A, Kachler S, Klotz KN, Marabese I, Luongo L, Maione S, Grifantini M (2009) N 6-Cycloalkyl- and N 6-bicycloalkyl-C5′(C2′)-modified adenosine derivatives as high-affinity and selective agonists at the human A1 adenosine receptor with antinociceptive effects in mice. J Med Chem 52:3430–3430
van der Wenden EM, Carnielli M, Roelen HCPF, Lorenzen A, von Frijtag Drabbe Künzel JK, IJzerman AP (1998) Ribose-modified adenosine analogs as potential partial agonists for the adenosine receptor. J Med Chem 41:102–108
Jacobson KA, Klutz AM, Tosh DK, Ivanov AA, Preti D, Baraldi PG (2009) Medicinal chemistry of the A3 adenosine receptor: agonists, antagonists, and receptor engineering. In: HEP adenosine receptors in health and disease, Springer, WilsonC, Mustafa J (eds) Handb Exp Pharmacol 193:123–159
van der Horst E, van der Pijl R, Mulder-Krieger T, Bender A, IJzerman AP (2011) Substructure-based virtual screening for adenosine A2A receptor ligands. Chem Med Chem 6:2301–2311
Brunschweiger A, Müller CE (2006) P2 receptors activated by uracil nucleotides—an update. Curr Med Chem 13:289–312
Robichaud J, Fournier JF, Gagne S, Gauthier JY, Hamel M, Han Y, Hénault M, Kargman S, Levesque JF, Mamane Y, Mancini J, Morin N, Mulrooney E, Wu J, Black WC (2011) Applying the pro-drug approach to afford highly bioavailable antagonists of P2Y14. Bioorg Med Chem Lett 21:4366–4368
Chhatriwala M, Ravi RG, Patel RI, Boyer JL, Jacobson KA, Harden TK (2004) Induction of novel agonist selectivity for the ADP-activated P2Y1 receptor versus the ADP-activated P2Y12 and P2Y13 receptors by conformational constraint of an ADP analogue. J Pharm Exp Therap 311:1038–1043
Yelovitch S, Camden J, Weisman GA, Fischer B (2012) Boranophosphate isoster controls P2Y-receptor subtype selectivity and metabolic stability of dinucleoside polyphosphate analogues. J Med Chem 55:437-448
Cattaneo M, Lecchi A, Joshi BV, Ohno M, Besada P, Tchilibon S, Lombardi R, Bischofberger N, Harden TK, Jacobson KA (2004) Antiaggregatory activity in human platelets of potent antagonists of the P2Y1 receptor. Biochem Pharmacol 68:1995–2002
Pfefferkorn JA, Choi C, Winters T, Kennedy R, Chi L, Perrin LA, Ping YW, McClanahan T, Schroeder R, Leininger MT, Geyer A, Schefzick S, Atherton J (2008) P2Y1 receptor antagonists as novel antithrombotic agents. Bioorg Med Chem Lett 18:3338–3343
Eliahu S, Barr HM, Camden J, Weisman GA, Fischer B (2010) A novel insulin secretagogue based on a dinucleoside polyphosphate scaffold. J Med Chem 53:2472–2481
Jacobson KA, Boeynaems J-M (2010) P2Y nucleotide receptors: promise of therapeutic applications. Drug Disc Today 15:570–578
Harden TK, Sesma JI, Fricks IP, Lazarowski ER (2010) Signaling and pharmacological properties of the P2Y14 receptor. Acta Physiol 199:149–160
Meis S, Hamacher A, Hongwiset D, Marzian C, Wiese M, Eckstein N, Royer HD, Communi D, Boeynaems JM, Hausmann R, Schmalzing G, Kassack MU (2010) NF546 [4,4′-(carbonylbis(imino-3,1-phenylene-carbonylimino-3,1-(4-methyl-phenylene)-carbonylimino))-bis(1,3-xylene-alpha, alpha′-diphosphonic acid) tetrasodium salt] is a non-nucleotide P2Y11 agonist and stimulates release of interleukin-8 from human monocyte-derived dendritic cells. J Pharm Exp Therap 332:238–247
Felix R, Martin S, Pinion S, Crawford DJ (2012) Development of a comprehensive set of P2 receptor pharmacological research compounds. Purinerg Signal 8(Suppl 1):101–112
Zhao J, Du Y, Horton JR, Upadhyay AK, Lou B, Bai Y, Zhang X, Du L, Li M, Wang B, Zhang L, Barbieri JT, Khuri FR, Cheng X, Fu H (2011) Discovery and structural characterization of a small molecule 14-3-3 protein–protein interaction inhibitor. Proc Natl Acad Sci USA 108:16212–16216
Jacobson KA, Gao ZG, Göblyös A, Ijzerman AP (2011) Allosteric modulators of purine and pyrimidine receptors. Adv Pharmacol 61:187–221
Welihinda AA, Amento EP (2011) Functional characterization of an allosteric enhancer of the adenosine A2a receptor that inhibits pro-inflammatory cytokine production. [abstract]. Arthritis Rheum 63(Suppl10):1812
Gessi S, Merighi S, Varani K, Borea PA (2011) Adenosine receptors in health and disease. Adv Pharmacol 61:41–75
Erlinge D (2011) P2Y receptors in health and disease. Adv Pharmacol 61:417–439
Cristalli G, Müller CE, Volpini R (2009) Recent developments in adenosine A2A receptor ligands. Handb Exp Pharmacol 193:59–98
Fishman P, Bar-Yehuda S, Liang BT, Jacobson KA (2012) Pharmacological and therapeutic effects of A3 adenosine receptor agonists. Drug Discov Today. doi:10.1016/j.drudis.2011.10.007
Koeppen M, Eckle T, Eltzschig HK (2011) Interplay of hypoxia and A2B adenosine receptors in tissue protection. Adv Pharmacol 61:145–186
Feoktistov I, Biaggioni I (2011) Role of adenosine A2B receptors in inflammation. Adv Pharmacol 61:115–144
Haskó G, Linden J, Cronstein B, Pacher P (2008) Adenosine receptors: therapeutic aspects for inflammatory and immune diseases. Nat Rev Drug Discov 7:759–770
Field JJ, Nathan DG, Linden J (2011) Targeting iNKT cells for the treatment of sickle cell disease. Clin Immunol 140:177–183
Albrecht-Küpper BE, Leineweber K, Nell PG (2012) Partial adenosine A1 receptor agonists for cardiovascular therapies. Purinergic Signal 8(Suppl 1):S91–S99
Morello S, Sorrentino R, Pinto A (2009) Adenosine A2a receptor agonists as regulators of inflammation: pharmacology and therapeutic opportunities. J Receptor Ligand Channel Res 2:11–17
Aherne CM, Kewley EM, Eltzschig HK (2011) The resurgence of A2B adenosine receptor signaling. Biochim Biophys Acta 1808:1329–1339
Feoktistov I, Biaggioni I, Cronstein BN (2009) Adenosine receptors in wound healing, fibrosis and angiogenesis. Handb Exp Pharmacol 193:383–397
Cronstein BN (2011) Adenosine receptors and fibrosis: a translational review. F1000 Biology Reports 3:21
Koupenova M, Johnson-Cox H, Vezeridis A, Gavras H, Yang D, Zannis V, Ravid K (2012) The A2b adenosine receptor regulates hyperlipidemia and atherosclerosis. Circulation 125:354–363
Shook BC, Jackson PF (2011) Adenosine A2A receptor antagonists and Parkinson’s disease. ACS Chem Neurosci 2:555–567
Ohta A, Sitkovsky M (2011) Methylxanthines, inflammation, and cancer: fundamental mechanisms. Handb Exp Pharmacol 200:469–481
von Kügelgen I, Harden TK (2011) Molecular pharmacology, physiology, and structure of the P2Y receptors. Adv Pharmacol 61:373–415
Lämmer AB, Beck A, Grummich B, Förschler A, Krügel T, Kahn T, Schneider D, Illes P, Franke H, Krügel U (2011) The P2 receptor antagonist PPADS supports recovery from experimental stroke in vivo. PLoS One 6:e19983
Balasubramanian R, Ruiz de Azua I, Wess J, Jacobson KA (2010) Activation of distinct P2Y receptor subtypes stimulates insulin secretion and cytoprotection in MIN6 mouse pancreatic β cells. Biochem Pharmacol 79:1317–1326
Tan C, Salehi A, Svensson S, Olde B, Erlinge D (2010) ADP receptor P2Y13 induce apoptosis in pancreatic beta-cells. Cell Mol Life Sci 67:445–453
Franke H, Krügel U, Illes P (2006) P2 receptors and neuronal injury. Pflugers Arch 452:622–644
Wei Q, Costanzi S, Liu QZ, Gao ZG, Jacobson KA (2011) Activation of the P2Y1 receptor induces apoptosis and inhibits proliferation of prostate cancer cells. Biochem Pharmacol 82:418–425
Hechler B, Freund M, Ravanat C, Magnenat S, Cazenave JP, Gachet C (2008) Reduced atherosclerotic lesions in P2Y1/apolipoprotein E double-knockout mice: the contribution of non-hematopoietic-derived P2Y1 receptors. Circulation 118:754–763
Gendaszewska-Darmach E, Kucharska M (2011) Nucleotide receptors as targets in the pharmacological enhancement of dermal wound healing. Purinergic Signal 7:193–206
Cohen R, Shainberg A, Hochhauser E, Cheporko Y, Tobar JA, Birk E, Pinhas L, Leipziger J, Don J, Porat E (2011) UTP reduces infarct size and improves mice heart function after myocardial infarct via P2Y2 receptor. Biochem Pharmacol 82:1126–1133
Ghanem E, Robaye B, Leal T, Leipziger J, Van Driessche W, Beauwens R, Boeynaems JM (2005) The role of epithelial P2Y2 and P2Y4 receptors in the regulation of intestinal chloride secretion. Br J Pharmacol 146:364–369
Sassmann A, Gier B, Gröne HJ, Drews G, Offermanns S, Wettschureck N (2010) The Gq/G11-mediated signaling pathway is critical for autocrine potentiation of insulin secretion in mice. J Clin Invest 120:2184–2193
Riegel AK, Faigle M, Zug S, Rosenberger P, Robaye B, Boeynaems JM, Idzko M, Eltzschig HK (2011) Selective induction of endothelial P2Y6 nucleotide receptor promotes vascular inflammation. Blood 117:2548–2555
Wilkin F, Duhant X, Bruyns C, Suarez-Huerta N, Boeynaems JM, Robaye B (2001) The P2Y11 receptor mediates the ATP-induced maturation of human monocyte-derived dendritic cells. J Immunol 166:7172–7177
Tozaki-Saitoh H, Tsuda M, Miyata H, Ueda K, Kohsaka S, Inoue K (2008) P2Y12 receptors in spinal microglia are required for neuropathic pain after peripheral nerve injury. J Neurosci 28:4949–4956
Koizumi S, Shigemoto-Mogami Y, Nasu-Tada K, Shinozaki Y, Ohsawa K, Tsuda M, Joshi BV, Jacobson KA, Kohsaka S, Inoue K (2007) UDP acting at P2Y6 receptors is a novel mediator of microglial phagocytosis. Nature 446:1091–1095
Boeynaems JM, Sirtori CR (2010) The unexpected roles of extracellular ADP and P2Y13 receptor in reverse cholesterol transport. Purinergic Signal 6:361–363
Zippel N, Limbach CA, Ratajski N, Urban C, Pansky A, Luparello C, Kassack MU, Tobiasch E (2011) Purinergic receptors influence the differentiation of human mesenchymal stem cells. Stem Cells Dev. doi:10.1089/scd.2010.0576
Zhang X, Alagille D, Koren AO, Cosgrove K, Seibyl JP, Batis JC, Tamagnan GD (2009) Synthesis of a small library of A2A receptor antagonists for PET/SPECT imaging and in vivo evaluation of [123I]-MNI-420 in nonhuman primate. ACS 238th Natl Meeting, Abstr. MEDI469, Aug. 2009, Washington DC
Cohen MV, Yang X, Downey JM (2010) A2b adenosine receptors can change their spots. Br J Pharmacol 159:1595–1597
Feoktistov I, Goldstein AE, Biaggioni I (1999) Role of p38 mitogen-activated protein kinase and extracellular signal-regulated protein kinase kinase in adenosine A2B receptor-mediated interleukin-8 production in human mast cells. Mol Pharmacol 55:726–734
Gao Z, Chen T, Weber MJ, Linden J (1999) A2B adenosine and P2Y2 receptors stimulate mitogen-activated protein kinase in human embryonic kidney-293 cells. Cross-talk between cyclic AMP and protein kinase c pathways. J Biol Chem 274:5972–5980
Linden J, Auchampach JA, Jin X, Figler RA (1998) The structure and function of A1 and A2B adenosine receptors. Life Sci 62:1519–1524
Ryzhov S, Goldstein AE, Biaggioni I, Feoktistov I (2006) Cross-talk between Gs- and Gq-coupled pathways in regulation of interleukin-4 by A2B adenosine receptors in human mast cells. Mol Pharmacol 70:727–735
Rieger JM, Brown ML, Sullivan GW, Linden J, Macdonald TL (2001) Design, synthesis, and evaluation of novel A2A adenosine receptor agonists. J Med Chem 44:531–539
Baraldi PG, Baraldi S, Saponaro G, Preti D, Romagnoli R, Piccagli L, Cavalli A, Recanatini M, Moorman AR, Zaid AN, Katia Varani KA, Borea PA, Tabrizi MA (2012) Novel 1,3-dipropyl-8-(3-benzimidazol-2-yl-methoxy-1-methylpyrazol-5-yl)xanthines as potent and selective A2B adenosine receptor antagonists. J Med Chem 55:797–811
Ivanov AA, Wang B, Klutz AM, Chen VL, Gao ZG, Jacobson KA (2008) Probing distal regions of the A2B adenosine receptor by quantitative structure–activity relationship modeling of known and novel agonists. J Med Chem 51:2088–2099
Fossa P, Pestarino M, Menozzi G, Mosti L, Schenone S, Ranise A, Bondavalli F, Trincavelli ML, Lucacchini A, Martini C (2005) New pyrazolo[3,4-b]pyridones as selective A1 adenosine receptor antagonists: synthesis, biological evaluation and molecular modelling studies. Org Biomol Chem 3:2262–2270
Acknowledgements
Supported by the NIDDK Intramural Research Program, National Institutes of Health.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Jacobson, K.A., Balasubramanian, R., Deflorian, F. et al. G protein-coupled adenosine (P1) and P2Y receptors: ligand design and receptor interactions. Purinergic Signalling 8, 419–436 (2012). https://doi.org/10.1007/s11302-012-9294-7
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11302-012-9294-7